Cancer researchers have identified six gene markers present in early stage non-small cell lung cancer (NSCLC) that show promise in helping oncologists better identify which tumors will relapse after curative surgery, according to a study presented a…
New data shows that people exposed to the mineral erionite found in the gravel of road materials in North Dakota may be at significantly increased risk of developing mesothelioma, a type of lung cancer most often associated with asbestos exposure, a…
A new study shows that a combination of epigenetic therapy and molecular targeted therapy has promising results at combating advanced lung cancer according to research presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology. T…
— Ipilimumab used in combination with paclitaxel/carboplatin for stage IIIb/IV non-small cell lung cancer showed superior results in progression free survival when compared to paclitaxel/carboplatin alone, according to research presented at the 20…
A new study shows that a new type of targeted radiation therapy called stereotactic radiation therapy is just as good as surgery for patients aged 75 and older with early-stage lung cancer, according to research presented at the 2010 Chicago Multidi…
In patients with metastatic breast cancer, immune cells from a genetically matched donor can attack and shrink tumors, researchers from the National Cancer Institute (NCI) announced today at the Annual Meeting of the American Society of Clinical Oncology in Chicago. This is the first time researchers have clearly demonstrated this type of immune response, known as a graft-versus-tumor effect, acting against breast cancer.
Breast cancer in men is usually detected when the tumors are bigger, have spread and may be more aggressive, compared to diagnosis of the disease in women, concludes the largest study ever conducted of male breast cancer. The findings, presented at the annual meeting of the American Society of Clinical Oncology, suggest both that breast cancer in men may have some important biological differences from the female disease, and that men are seemingly less aware than they should be that they can develop breast cancer.
Adding docetaxel to the most commonly used combination chemotherapy improved tumor regression rate, delayed tumor growth and prolonged survival for patients with advanced stomach cancer, according to interim results of a Phase III international clinical trial presented at the annual meeting of the American Society of Clinical Oncology.